Amgen To Pay $780M To Settle Drug Sales Suits

Law360, New York (October 24, 2011, 10:50 PM EDT) -- Amgen Inc. said Monday it would pay $780 million to settle allegations over its sales and marketing practices stemming from civil and criminal investigations — including Medicaid claims and a whistleblower suit accusing the drugmaker of bribing health care providers to buy its drug Aranesp.

In a third-quarter statement, Amgen said the proposed settlement amount would resolve the qui tam suit launched by ex-Amgen employee Kassie Westmoreland, as well as nine other whistleblower suits, state Medicaid claims and criminal and civil investigations conducted by U.S. attorney's...
To view the full article, register now.